文献速递心律失常

CHA2DS2-VASc评分为1分的房颤患者卒中与出血风险:挪威AFNOR研究

Stroke and bleeding risk in atrial fibrillation with CHA2DS2-VASC risk score of one: the Norwegian AFNOR study.
PubMed 文献 · Eur Heart J · 2024-01-01

结果显示,口服抗凝治疗与缺血性卒中风险降低相关(aHR 0.47 [0.37-0.59]),虽增加大出血风险(aHR 1.37 [1.16-1.63]),但总体临床结局(缺血性卒中、大出血和死亡复合终点)更优(aHR 0.57 [0.51-0.63])。

要点

  • CHA2DS2-VASc评分为1分的房颤患者,口服抗凝治疗与缺血性卒中风险降低相关(aHR 0.47)。
  • 口服抗凝治疗增加大出血风险(aHR 1.37),但复合终点(缺血性卒中、大出血和死亡)风险更低(aHR 0.57)。
  • 未抗凝房颤患者较相同风险评分的无房颤人群缺血性卒中风险更高(aHR 2.47)。

核心结论

  • 在卒中中等风险的房颤患者中,口服抗凝治疗与总体临床结局更优相关。
  • 未抗凝的房颤患者相比相同风险评分的无房颤人群缺血性卒中风险更高。

研究设计与样本

  • 基于挪威全国性队列的观察性研究,纳入1 118 762名个体,其中34 460名房颤患者。
  • 采用Cox回归模型计算调整后风险比(aHR)及95%置信区间。

主要发现

  • 房颤患者中,口服抗凝治疗者缺血性卒中发生率为0.51%/人年,未治疗者为1.05%/人年(aHR 0.47 [0.37-0.59])。
  • 颅内出血发生率在口服抗凝治疗者为0.28%/人年,未治疗者为0.19%/人年(aHR 1.23 [0.88-1.72])。
  • 口服抗凝治疗与大出血风险增加相关(aHR 1.37 [1.16-1.63])。
  • 口服抗凝治疗与缺血性卒中、大出血和死亡复合终点风险降低相关(aHR 0.57 [0.51-0.63])。
  • 未抗凝房颤患者相比相同风险评分的无房颤个体,缺血性卒中风险更高(aHR 2.47 [2.17-2.81])。

临床怎么用

  • 对于CHA2DS2-VASc评分为1分的房颤患者,口服抗凝治疗可考虑用于降低缺血性卒中风险。
  • 决策时需权衡口服抗凝治疗增加的大出血风险与复合终点获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: The benefit of oral anticoagulant (OAC) therapy in atrial fibrillation (AF) and intermediate stroke risk is debated. In a nationwide Norwegian cohort with a non-sex CHA2DS2-VASc risk score of one, this study aimed to investigate (i) stroke and bleeding risk in AF patients with and without OAC treatment, and (ii) the risk of stroke in non-anticoagulated individuals with and without AF. METHODS: A total of 1 118 762 individuals including 34 460 AF patients were followed during 2011-18 until ischaemic stroke, intracranial haemorrhage, increased CHA2DS2-VASc score, or study end. One-year incidence rates (IRs) were calculated as events per 100 person-years (%/py). Cox regression models provided adjusted hazard ratios (aHRs [95% confidence intervals]). RESULTS: Among AF patients, the ischaemic stroke IR was 0.51%/py in OAC users and 1.05%/py in non-users (aHR 0.47 [0.37-0.59]). Intracranial haemorrhage IR was 0.28%/py in OAC users and 0.19%/py in non-users (aHR 1.23 [0.88-1.72]). Oral anticoagulant use was associated with an increased risk of major bleeding (aHR 1.37 [1.16-1.63]) but lower risk of the combined outcome of ischaemic stroke, major bleeding, and mortality (aHR 0.57 [0.51-0.63]). Non-anticoagulated individuals with AF had higher risk of ischaemic stroke compared to non-AF individuals with the same risk profile (aHR 2.47 [2.17-2.81]). CONCLUSIONS: In AF patients at intermediate risk of stroke, OAC use was associated with overall favourable clinical outcomes. Non-anticoagulated AF patients had higher risk of ischaemic stroke compared to the general population without AF with the same risk profile.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Anjum, Ariansen, Hjellvik, et al. Stroke and bleeding risk in atrial fibrillation with CHA2DS2-VASC risk score of one: the Norwegian AFNOR study. Eur Heart J. 2024. PMID: 37995254. doi:10.1093/eurheartj/ehad659

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。